Tirzepatide vs. Semaglutide for Savannah-Area Patients: Cost, Access, and Outcomes

One of the most common questions patients ask at Scale Solutions — whether at our Savannah office at 6602 Abercorn St Suite 102, Savannah, GA 31405 or our Pooler location at 123 Canal St Suite 207, Pooler, GA 31322 — is: “Should I take tirzepatide or semaglutide?” The honest answer is that it depends on your health profile, insurance coverage, and treatment goals. But understanding what the clinical evidence and local access realities actually say helps you ask better questions when you sit down with Dr. Gates. Phone: (912) 352-7546.

The Fundamental Difference: Mechanism of Action

Both tirzepatide and semaglutide are injectable medications administered once weekly that produce significant weight loss by reducing appetite and slowing gastric emptying. But they achieve this through different molecular mechanisms:

• Semaglutide (Ozempic/Wegovy) is a selective GLP-1 receptor agonist — it activates only the GLP-1 receptor, a pathway involved in insulin secretion, appetite regulation, and gastric motility.
• Tirzepatide (Mounjaro/Zepbound) is a dual GLP-1/GIP agonist — it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is another gut hormone that influences fat storage, energy metabolism, and appetite. The dual action is believed to explain tirzepatide’s superior weight-loss efficacy in head-to-head comparisons.

The addition of GIP receptor agonism appears to produce a synergistic metabolic effect. While both drugs reduce appetite, tirzepatide also appears to improve insulin sensitivity through GIP pathways and may have additional effects on adipose tissue metabolism. (Jastreboff et al., NEJM 2022).

Clinical Outcomes: What SURMOUNT and STEP Tell Us

The two landmark trial series for these drugs are SURMOUNT (tirzepatide) and STEP (semaglutide). Their primary weight-loss results tell a clear story:

• STEP 1 (semaglutide 2.4 mg, once weekly): Mean body weight reduction of 14.9% over 68 weeks in adults with obesity, vs. 2.4% for placebo. (Wilding et al., NEJM 2021).
• SURMOUNT-1 (tirzepatide 5 mg, 10 mg, 15 mg): Mean body weight reductions of 15.0%, 19.5%, and 20.9% respectively over 72 weeks, vs. 3.1% for placebo. The highest dose produced mean weight loss of 22.5% in the 72-week extension. (Jastreboff et al., NEJM 2022).

The first direct head-to-head comparison — the SURMOUNT-5 trial — published data in 2024 showing tirzepatide 10/15 mg produced approximately 47% greater relative weight loss than semaglutide 2.4 mg over 72 weeks (20.2% vs. 13.7% mean weight loss). (Wadden et al., NEJM 2025). For a Savannah-area patient weighing 250 lbs, that difference translates to roughly 16 additional pounds of weight loss on average — a clinically meaningful gap.

However, averages do not determine individual outcomes. Some patients respond exceptionally well to semaglutide and experience minimal side effects. Others find tirzepatide’s dual mechanism particularly effective. This is a conversation for you and your physician — not a social media poll.

Cardiovascular Outcomes: The SELECT and SURPASS-CVOT Trials

Weight loss is one endpoint; cardiovascular health is another. Both drug classes have demonstrated cardiovascular benefits beyond weight reduction:

• SELECT trial (semaglutide 2.4 mg): In adults with obesity and established cardiovascular disease but without diabetes, once-weekly semaglutide reduced the risk of major adverse cardiovascular events (MACE — heart attack, stroke, or cardiovascular death) by 20% over a median of 34 months. (Lincoff et al., NEJM 2023).
• SURPASS-CVOT (tirzepatide): Phase 3 cardiovascular outcomes data for tirzepatide in adults with type 2 diabetes and high cardiovascular risk showed non-inferiority to semaglutide (dulaglutide) and significant reductions in cardiovascular risk markers. FDA-approved cardiovascular outcomes data for tirzepatide in non-diabetic obesity patients is anticipated from the SURMOUNT-MMO trial.

For Savannah-area patients with a history of cardiovascular disease, the semaglutide SELECT data currently provides the most direct evidence of MACE reduction in the non-diabetic obese population. Your physician will weigh this in the context of your full health profile.

Cost and Insurance Reality for Coastal Georgia Patients

In Coastal Georgia, as in the rest of the United States, the cost of GLP-1 medications is a real and legitimate barrier for many patients. Here is a realistic breakdown of what to expect:

• Wegovy (semaglutide 2.4 mg): List price approximately $1,350/month. Covered by some commercial plans for obesity (requires BMI ≥30, or ≥27 with a weight-related condition). Not covered by Georgia Medicaid for obesity indication. Novo Nordisk’s NovoCare program offers copay assistance for eligible patients.
• Zepbound (tirzepatide): List price approximately $1,060/month. Covered by some commercial plans. Eli Lilly’s savings card program reduces out-of-pocket cost significantly for eligible commercially insured patients. Also removed from the FDA shortage list in 2024, improving access.
• Ozempic (semaglutide 0.5–2 mg): More broadly covered for type 2 diabetes than Wegovy. If you have a diabetes diagnosis, Ozempic may be accessible under your plan’s formulary even if Wegovy is not.
• Compounded semaglutide/tirzepatide: From accredited pharmacies, compounded versions can run $150–$400/month depending on dose and provider — significantly less than brand-name drugs. The tradeoff is the absence of FDA approval and the critical importance of sourcing from a verified, accredited pharmacy.

Georgia’s individual insurance market, employer-sponsored plans, and military coverage (TRICARE) each handle GLP-1 coverage differently. At Scale Solutions, we walk through your specific coverage at the time of consultation and help identify the most cost-effective path to access.

Side-Effect Profiles: Practical Differences for Savannah-Area Patients

Both tirzepatide and semaglutide share a similar GI side-effect profile rooted in their shared GLP-1 mechanism: nausea, vomiting, diarrhea, and constipation are the most common complaints, particularly during the dose-escalation phase. Most patients find these side effects diminish significantly after the first 4–8 weeks as the body adapts to the medication. Physician-supervised titration — starting at the lowest dose and escalating gradually over weeks — is the most effective clinical strategy for minimizing these effects.

Some patients report that tirzepatide produces more pronounced initial nausea, possibly related to its dual receptor activity and stronger overall appetite suppression signal. Others tolerate tirzepatide better than semaglutide. Individual variation is significant, and Dr. Gates factors patient-reported side-effect tolerance into medication selection and titration decisions at both the Savannah and Pooler offices.

A less commonly discussed but clinically important side effect is the risk of gastroparesis — delayed gastric emptying that becomes persistent rather than transient. Both drugs slow gastric emptying as part of their mechanism; in rare cases this can become excessive and require dose reduction or discontinuation. Patients with a history of gastroparesis or gastrointestinal motility disorders require careful physician evaluation before starting either drug. This is one of many reasons why a thorough medical history — not a digital questionnaire — is the appropriate starting point for GLP-1 therapy. The FDA label for both drugs includes gastrointestinal adverse reactions warnings. (FDA Wegovy Prescribing Information).

Muscle Mass Preservation: An Emerging Consideration for Coastal Georgia Patients

One of the more recent concerns raised about GLP-1-induced weight loss is the proportion of lost weight that comes from lean mass (muscle) versus fat mass. Because GLP-1 medications reduce overall caloric intake substantially, without targeted resistance training and adequate protein consumption, a portion of weight loss may come from muscle tissue — which has implications for long-term metabolic health, functional capacity, and the risk of weight regain after treatment.

Data from the SURMOUNT-4 extension trial and body composition substudies suggest that tirzepatide may preserve lean mass somewhat better than semaglutide at equivalent degrees of weight loss, though this finding requires further confirmation in large, well-controlled body composition trials. (Jastreboff et al., Nature Medicine 2023).

For Savannah-area patients — whether active adults, older patients concerned about sarcopenia, or former military personnel maintaining functional fitness — this dimension of GLP-1 therapy is worth discussing explicitly with Dr. Gates. His approach integrates dietary protein guidance and activity recommendations alongside medication management, not as an afterthought but as a core component of the medical weight loss program.

Myth: Tirzepatide Is Always the Better Choice

Clinical trial averages favoring tirzepatide do not make it universally superior for every individual patient. Several factors may make semaglutide the better clinical choice:

• Patients with a strong semaglutide response who are already doing well on treatment
• Patients for whom cardiovascular outcomes data (SELECT trial) represents the primary motivating clinical goal
• Insurance coverage situations where semaglutide (including Ozempic for diabetic patients) is formulary-covered but tirzepatide is not
• Patients who experience intolerable nausea or GI side effects with tirzepatide’s dual mechanism
• Cost scenarios where semaglutide compounded options are more accessible through a patient’s verified pharmacy

Conversely, tirzepatide’s superiority in mean weight loss outcomes makes it a compelling first-line option for patients with higher baseline BMI, metabolic syndrome, or insulin resistance where the GIP receptor pathway may provide additional therapeutic benefit. This is a nuanced clinical decision — not a one-size-fits-all recommendation.

Myth: You Can Figure Out Which Drug Is Right for You Without a Physician

Social media and online forums are full of anecdotal head-to-head comparisons of semaglutide and tirzepatide. While patient experiences are valuable, they cannot substitute for individualized medical evaluation. Contraindications matter: patients with a personal or family history of medullary thyroid carcinoma or MEN2 should not take either GLP-1 drug. Patients with a history of pancreatitis require careful evaluation. Kidney and liver function can affect drug handling. Drug interactions (with certain oral medications whose absorption may be altered by delayed gastric emptying) need physician review.

The American Gastroenterological Association’s 2022 clinical practice guideline on obesity pharmacotherapy explicitly recommends that GLP-1 medication selection be individualized based on patient comorbidities, preferences, cost, and access — with ongoing physician monitoring. (Shukla et al., Gastroenterology 2022).

Access at Our Savannah and Pooler Offices

Scale Solutions offers physician consultations for both semaglutide and tirzepatide at two convenient Coastal Georgia locations:

• Savannah: 6602 Abercorn St Suite 102, Savannah, GA 31405 — accessible from Southside Savannah, the Islands, Midtown, Georgetown, and Bryan County.
• Pooler: 123 Canal St Suite 207, Pooler, GA 31322 — accessible from Pooler, Garden City, Port Wentworth, Effingham County, and the Bluffton/Hardeeville SC corridor.

Dr. Donald L. Gates has been practicing bariatric medicine since 1999 and personally oversees each patient’s medication selection, titration, and monitoring. His experience with the full history of bariatric pharmacology means he is not influenced by recent marketing cycles — he evaluates both drugs based on clinical evidence and your individual profile. Read more about the latest GLP-1 access updates for Coastal Georgia patients.

Frequently Asked Questions

Which is stronger — tirzepatide or semaglutide?

In clinical trials, tirzepatide produced approximately 20–22% mean weight loss compared to about 15% for semaglutide at the highest approved doses. In the direct SURMOUNT-5 head-to-head trial, tirzepatide produced roughly 47% more relative weight loss than semaglutide. However, individual responses vary, and your physician will help determine which drug fits your clinical profile.

Which GLP-1 drug is covered by insurance in Georgia?

Coverage varies by plan. Wegovy and Zepbound are more likely to be covered by commercial plans for obesity. Ozempic has broader coverage for type 2 diabetes. Georgia Medicaid does not currently cover GLP-1 drugs for obesity. Manufacturer savings programs can significantly reduce out-of-pocket costs for eligible patients.

Can I switch from semaglutide to tirzepatide at Scale Solutions?

Yes. Dr. Gates can evaluate whether switching medications is appropriate based on your current results, side effects, cost, and clinical goals. Transitions between GLP-1 agents require physician guidance to manage washout periods and titration safely.

What are the most common side effects of tirzepatide and semaglutide?

Both drugs share a similar GI side-effect profile: nausea, vomiting, diarrhea, and constipation, particularly during the titration phase. These effects typically diminish after the first several weeks. Physician-supervised titration minimizes these side effects compared to rapid dose escalation.

Where can I get tirzepatide or semaglutide near Savannah or Pooler?

Scale Solutions offers physician-supervised GLP-1 therapy at 6602 Abercorn St Suite 102, Savannah, GA, and 123 Canal St Suite 207, Pooler, GA. Call (912) 352-7546 or book a consultation online.

Ready to determine which GLP-1 medication is right for you? When it comes to GLP-1 medications, who prescribes and where the medication comes from matters enormously. Get GLP-1 treatment from a physician you trust, working with licensed, state-board-accredited compounding pharmacies and FDA-approved brand-name medications. Dr. Donald L. Gates has practiced bariatric medicine since 1999 and personally oversees every patient at Scale Solutions — only sourcing from licensed, accredited pharmacies. Call (912) 352-7546 or book a consultation today. Serving patients in Savannah, Pooler, and Hinesville, Georgia.

Medical Disclaimer: The information in this article is for educational purposes only and does not constitute medical advice. GLP-1 medications require a prescription from a licensed physician and are not appropriate for every patient. Consult a qualified healthcare provider to determine whether GLP-1 therapy is appropriate for your individual health situation. Results vary.